Answers are grounded in this paper and cite their sources.
Background Rheumatoid arthritis is a chronic inflammatory disease that is estimated to affect 17.6 million people worldwide. Even with the development of biologic therapies, 30–40% of patients do not respond to the first-line therapy and others lose their response to therapy over time. Current serological and clinical predictors show limited accuracy, highlighting the need for more reliable treatment-response biomarkers. Objective To evaluate critically the published evidence linking pretreatment gut microbiota composition to subsequent response to conventional synthetic and biologic DMARDs in rheumatoid arthritis, to appraise the pharmaco microbiomic mechanisms through which the microbiome may modify drug action, and to map the key methodological challenges that restrict translation to clinical practice. Search Strategy and Methods A structured narrative review was conducted with a reproducible bibliographic search of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, and DOAJ covered January 2015–April 2025. After deduplication and two-reviewer screening, 55 studies were included. Due to methodological heterogeneity, findings were synthesized narratively rather than by meta-analysis. Key Findings Pretreatment abundance of butyrate-producing Lachnospiraceae principally Subdoligranulum (AUC = 0.669) and Fusicatenibacter (AUC = 0.665)—was reproducibly associated with favourable csDMARD outcomes at six months. A composite gut microbiome-based model achieved AUC = 0.65 in independent validation (IMRABIOME cohort), which exceeded models relying exclusively on standard clinical variables (approximately AUC = 0.61). Prevotella copri was found in 75% of newly diagnosed RA patients versus 21.4% of healthy controls (p < 0.001). Shannon alpha-diversity was substantially reduced across RA cohorts, with a pooled SMD of −0.61 (95% CI: −0.89 to −0.33) relative to healthy controls. Pharmacomicrobiomic experiments confirmed direct microbial catabolism of methotrexate by pretreatment faecal microbiota, establishing a plausible causal link between baseline microbiome composition and drug bioavailability. Conclusion Pretreatment gut microbiome composition may predict RA treatment response, but clinical translation requires large multicenter validation, standardized sequencing and bioinformatics, and ethnically diverse cohorts.
No takes yet. Share an insight, caveat, or question.
Kadhim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: